Last reviewed · How we verify
HRS-1893
At a glance
| Generic name | HRS-1893 |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants (PHASE1)
- A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects (PHASE1)
- A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction (PHASE2)
- A Trial of HRS-1893 in Healthy Volunteers (EARLY_PHASE1)
- Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function (PHASE1)
- A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy (PHASE2)
- A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy (PHASE3)
- A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-1893 CI brief — competitive landscape report
- HRS-1893 updates RSS · CI watch RSS
- Shandong Suncadia Medicine Co., Ltd. portfolio CI